|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fisusi FA and Akala EO: Drug combinations
in breast cancer therapy. Pharm Nanotechnol. 7:3–23. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McDonald ES, Clark AS, Tchou J, Zhang P
and Freedman GM: Clinical diagnosis and management of breast
cancer. J Nucl Med. 57 (Suppl 1):9S–16S. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma R, Sharma R, Khaket TP, Dutta C,
Chakraborty B and Mukherjee TK: Breast cancer metastasis: Putative
therapeutic role of vascular cell adhesion molecule-1. Cell Oncol
(Dordr). 40:199–208. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rashid NS, Grible JM, Clevenger CV and
Harrell JC: Breast cancer liver metastasis: Current and future
treatment approaches. Clin Exp Metastasis. 38:263–277. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sugie T: Immunotherapy for metastatic
breast cancer. Chin Clin Oncol. 7:282018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abu Samaan TM, Samec M, Liskova A, Kubatka
P and Büsselberg D: Paclitaxel's mechanistic and clinical effects
on breast cancer. Biomolecules. 9:7892019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chi Y, Xue J, Huang S, Xiu B, Su Y, Wang
W, Guo R, Wang L, Li L, Shao Z, et al: CapG promotes resistance to
paclitaxel in breast cancer through transactivation of PIK3R1/P50.
Theranostics. 9:6840–6855. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
AlFakeeh A and Brezden-Masley C:
Overcoming endocrine resistance in hormone receptor-positive breast
cancer. Curr Oncol. 25 (Suppl 1):S18–S27. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia ZH, Wang XG and Zhang H: Overcome
cancer drug resistance by targeting epigenetic modifications of
centrosome. Cancer Drug Resist. 2:210–224. 2019.PubMed/NCBI
|
|
11
|
Bi J, Ichu TA, Zanca C, Yang H, Zhang W,
Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, et al: Oncogene
amplification in growth factor signaling pathways renders cancers
dependent on membrane lipid remodeling. Cell Metab. 30:525–538.e8.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang Y, Wang Y, Wang Y, Wang N, Duan Q,
Wang S, Liu M, Bilal MA and Zheng Y: LPCAT1 promotes cutaneous
squamous cell carcinoma via EGFR-mediated protein kinase B/p38MAPK
signaling pathways. J Invest Dermatol. 142:303–313.e9. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He RQ, Li JD, Du XF, Dang YW, Yang LJ,
Huang ZG, Liu LM, Liao LF, Yang H and Chen G: LPCAT1 overexpression
promotes the progression of hepatocellular carcinoma. Cancer Cell
Int. 21:4422021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao T, Zhang Y, Ma X, Wei L, Hou Y, Sun R
and Jiang J: Elevated expression of LPCAT1 predicts a poor
prognosis and is correlated with the tumour microenvironment in
endometrial cancer. Cancer Cell Int. 21:2692021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu H, Miao YR, Jia LH, Yu QY, Zhang Q and
Guo AY: AnimalTFDB 3.0: A comprehensive resource for annotation and
prediction of animal transcription factors. Nucleic Acids Res.
47(D1): D33–D38. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Wu N, Zhang J, Wang H and Men X:
MiR-153-5p enhances the sensitivity of triple-negative breast
cancer cells to paclitaxel by inducing G2M phase arrest. Onco
Targets Ther. 13:4089–4097. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Verco S, Maulhardt H, Baltezor M, Williams
E, Iacobucci M, Wendt A, Verco J, Marin A, Campbell S, Dorman P and
diZerega G: Local administration of submicron particle paclitaxel
to solid carcinomas induces direct cytotoxicity and immune-mediated
tumoricidal effects without local or systemic toxicity: Preclinical
and clinical studies. Drug Deliv Transl Res. 11:1806–1817. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dan VM, Raveendran RS and Baby S:
Resistance to intervention: Paclitaxel in breast cancer. Mini Rev
Med Chem. 21:1237–1268. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mishra A, Srivastava A, Pateriya A, Tomar
MS, Mishra AK and Shrivastava A: Metabolic reprograming confers
tamoxifen resistance in breast cancer. Chem Biol Interact.
347:1096022021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Z, Li Z, Deng M, Liu B, Xin X, Zhao
Z, Zhang Y and Lv Q: Downregulation of GPSM2 is associated with
primary resistance to paclitaxel in breast cancer. Oncol Rep.
43:965–974. 2020.PubMed/NCBI
|
|
24
|
Ge X, Cao Z, Gu Y, Wang F, Li J, Han M,
Xia W, Yu Z and Lyu P: PFKFB3 potentially contributes to paclitaxel
resistance in breast cancer cells through TLR4 activation by
stimulating lactate production. Cell Mol Biol (Noisy-le-grand).
62:119–125. 2016.PubMed/NCBI
|
|
25
|
Nedeljković M and Damjanović A: Mechanisms
of chemotherapy resistance in triple-negative breast cancer-how we
can rise to the challenge. Cells. 8:9572019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang B and Tontonoz P: Phospholipid
remodeling in physiology and disease. Annu Rev Physiol. 81:165–188.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tao M, Luo J, Gu T, Yu X, Song Z, Jun Y,
Gu H, Han K, Huang X, Yu W, et al: LPCAT1 reprogramming cholesterol
metabolism promotes the progression of esophageal squamous cell
carcinoma. Cell Death Dis. 12:8452021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie H, Xiao R, He Y, He L, Xie C, Chen J
and Hong Y: MicroRNA-100 inhibits breast cancer cell proliferation,
invasion and migration by targeting FOXA1. Oncol Lett. 22:8162021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu L, Wang F, Fan W, Jin Z, Teng C and
Zhang J: lncRNA NEAT1 promotes the Taxol resistance of breast
cancer via sponging the miR-23a-3p-FOXA1 axis. Acta Biochim Biophys
Sin (Shanghai). 53:1198–1206. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Adams EJ, Karthaus WR, Hoover E, Liu D,
Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, et al:
FOXA1 mutations alter pioneering activity, differentiation and
prostate cancer phenotypes. Nature. 571:408–412. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Parolia A, Cieslik M, Chu SC, Xiao L,
Ouchi T, Zhang Y, Wang X, Vats P, Cao X, Pitchiaya S, et al:
Distinct structural classes of activating FOXA1 alterations in
advanced prostate cancer. Nature. 571:413–418. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arruabarrena-Aristorena A, Maag JLV,
Kittane S, Cai Y, Karthaus WR, Ladewig E, Park J, Kannan S,
Ferrando L, Cocco E, et al: FOXA1 mutations reveal distinct
chromatin profiles and influence therapeutic response in breast
cancer. Cancer Cell. 38:534–550.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He Y, Wang L, Wei T, Xiao YT, Sheng H, Su
H, Hollern DP, Zhang X, Ma J, Wen S, et al: FOXA1 overexpression
suppresses interferon signaling and immune response in cancer. J
Clin Invest. 131:e1470252021. View Article : Google Scholar : PubMed/NCBI
|
